title: Surface localization of glucosylceramide during Cryptococcus neoformans infection allows targeting as a potential antifungal.
abstract: Cryptococcus neoformans (Cn) is a significant human pathogen that, despite current treatments, continues to have a high morbidity rate especially in sub-Saharan Africa. The need for more tolerable and specific therapies has been clearly shown. In the search for novel drug targets, the gene for glucosylceramide synthase (GCS1) was deleted in Cn, resulting in a strain (Δgcs1) that does not produce glucosylceramide (GlcCer) and is avirulent in mouse models of infection. To understand the biology behind the connection between virulence and GlcCer, the production and localization of GlcCer must be characterized in conditions that are prohibitive to the growth of Δgcs1 (neutral pH and high CO(2)). These prohibitive conditions are physiologically similar to those found in the extracellular spaces of the lung during infection. Here, using immunofluorescence, we have shown that GlcCer localization to the cell surface is significantly increased during growth in these conditions and during infection. We further seek to exploit this localization by treatment with Cerezyme (Cz), a recombinant enzyme that metabolizes GlcCer, as a potential treatment for Cn. Cz treatment was found to reduce the amount of GlcCer in vitro, in cultures, and in Cn cells inhabiting the mouse lung. Treatment with Cz induced a membrane integrity defect in wild type Cn cells similar to Δgcs1. Cz treatment also reduced the in vitro growth of Cn in a dose and condition dependent manner. Finally, Cz treatment was shown to have a protective effect on survival in mice infected with Cn. Taken together, these studies have established the legitimacy of targeting the GlcCer and other related sphingolipid systems in the development of novel therapeutics.
authors.affiliation: Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, South Carolina, United States of America.
authors.forename: Ryan
authors.initials: R
authors.lastname: Rhome
authors.forename: Arpita
authors.initials: A
authors.lastname: Singh
authors.forename: Talar
authors.initials: T
authors.lastname: Kechichian
authors.forename: Monica
authors.initials: M
authors.lastname: Drago
authors.forename: Giulia
authors.initials: G
authors.lastname: Morace
authors.forename: Chiara
authors.initials: C
authors.lastname: Luberto
authors.forename: Maurizio
authors.initials: M
authors.lastname: Del Poeta
mesh_terms: D000818:Animals; D000935:Antifungal Agents / Q000627:therapeutic use*; D002462:Cell Membrane / Q000378:metabolism*; D003453:Cryptococcosis / Q000188:drug therapy*; D003455:Cryptococcus neoformans / Q000187:drug effects* / Q000472:pathogenicity; D005962:Glucosylceramidase / Q000172:deficiency / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D005963:Glucosylceramides / Q000378:metabolism*; D005964:Glucosyltransferases / Q000172:deficiency / Q000235:genetics; D051379:Mice; D016896:Treatment Outcome
chemical_list: D000935:Antifungal Agents; D005963:Glucosylceramides; D005964:Glucosyltransferases; C023246:ceramide glucosyltransferase; D005962:Glucosylceramidase; C090568:imiglucerase